Skip to main content
ADMA $13.36 +0.15%
ADMA logo
ADMA · Adma Biologics, Inc.
Track ADMA — free
Market Cap
$2.96B
Shares
221.85M
Volume · Nov 20 284.76K Avg daily vol (3M) 3.2M
All webcasts

Earnings call · FY2026 Q3

Adma Biologics, Inc. (ADMA) Q3 2026 Earnings Call

Concluded Nov 4, 2026
Nov 4, 2026
Period
FY2026 Q3
Runtime
—
Sources
2 artifacts
Revenue $141.10M +5.1% YoY
Diluted EPS $0.22 +46.7% YoY
Gross margin 70.8% +14.5 pp YoY
Net income $49.88M +36.9% YoY
Open full screen 8-K 10-Q

Executive readout · one minute

What the filings say

8-K earnings release · filed Nov 4, 2026
ADMA Biologics reported 3Q 2026 total revenue of $141.1 million, up 5% year-over-year, and GAAP net income of $49.9 million, up 37%; it reiterated FY2026 revenue guidance of at least $530 million while increasing adjusted earnings expectations.
10-Q report · filed Nov 4, 2026
ADMA Biologics reported third-quarter revenue of 141,102 and net income of 49,884, both in thousands, versus 134,224 and 36,428 in the prior-year quarter. Cash and cash equivalents were 124,555, also in thousands.

The audio replay and transcript follow the call.

Forward guidance

3 guided metrics

Management's latest ranges and targets are included below.

Research coverage

2 live sources

Open each available source without leaving this research workspace.

Research materials

Open the source you need; every reader stays inside this workspace.

Forward guidance

From the 8-K filed Nov 4, 2026.

Metric Guided
FY2026 total revenue
FY2026
at least $530M
FY2026 Adjusted Net Income
FY2026
at least $180M
FY2026 Adjusted EBITDA
FY2026
at least $275M

Quarter detail

How the reported period landed and where the business moved.

Revenue · segments

ADMA Bio Manufacturing Segment$141.04M +5.1% YoY
Plasma Collection Centers Segment$25,000

Capital returned

Buybacks · derived
$25.05M
Shares repurchased
2.72M
Full-screen source Call document